Klaus Podar

机构：Universitätsklinikum Krems, Karl Landsteiner University of Health Sciences · ORCID：0000-0002-7414-3632

发表论文 348 篇 · 总被引 18286 次 · h-index 73

代表论文

• PARP7 as a new target for activating anti-tumor immunity in cancer (2025 · EMBO Molecular Medicine · 被引 24)
• Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation (2024 · Journal for ImmunoTherapy of Cancer · 被引 15)
• Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR) (2023 · Cancers · 被引 9)
• The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma (2024 · Expert Opinion on Drug Discovery · 被引 7)
• Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity (2024 · Blood Cancer Journal · 被引 6)
• Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia (2025 · Cancer Letters · 被引 4)